Log in

Relevant bibliographies by topics / Anticancer treatments / Journal articles

To see the other types of publications on this topic, follow the link: Anticancer treatments.

Journal articles on the topic 'Anticancer treatments'

Author: Grafiati

Published: 4 June 2021

Last updated: 3 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anticancer treatments.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Toca-Muñoz, M., B. Mora-Rodríguez, A. Luna-Higuera, E. Valverde Alcalá, and I. M. Muñoz-Castillo. "Targeted anticancer treatments." European Journal of Hospital Pharmacy 19, no. 2 (2012): 185.1–185. http://dx.doi.org/10.1136/ejhpharm-2012-000074.264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ewer, Michael S., and Steven M. Ewer. "Cardiotoxicity of anticancer treatments." Nature Reviews Cardiology 12, no. 9 (2015): 547–58. http://dx.doi.org/10.1038/nrcardio.2015.65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Zarifa, Abdulrazzak, Aya Albittar, Peter Y. Kim, et al. "Cardiac toxicities of anticancer treatments." Current Opinion in Cardiology 34, no. 4 (2019): 441–50. http://dx.doi.org/10.1097/hco.0000000000000641.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ewer, Michael S., and Steven M. Ewer. "Erratum: Cardiotoxicity of anticancer treatments." Nature Reviews Cardiology 12, no. 11 (2015): 620. http://dx.doi.org/10.1038/nrcardio.2015.133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

D'Hondt, Lionel, Christophe Lonchay, Marc Andr�, and Jean-Luc Canon. "Oral mucositis induced by anticancer treatments: physiopathology and treatments." Therapeutics and Clinical Risk Management 2, no. 2 (2006): 159–68. http://dx.doi.org/10.2147/tcrm.2006.2.2.159.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Chen, Sheng-hong, William Forrester, and Galit Lahav. "Schedule-dependent interaction between anticancer treatments." Science 351, no. 6278 (2016): 1204–8. http://dx.doi.org/10.1126/science.aac5610.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Jouinot, Anne, Clara Vazeille, and François Goldwasser. "Resting energy metabolism and anticancer treatments." Current Opinion in Clinical Nutrition & Metabolic Care 21, no. 3 (2018): 145–51. http://dx.doi.org/10.1097/mco.0000000000000457.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Calvo, Anne Sophie, Juliette Rochefort, Marie José Javelot, Vianney Descroix, and Géraldine Lescaille. "Management of mTOR inhibitors oral mucositis: current state of knowledge." Journal of Oral Medicine and Oral Surgery 25, no. 1 (2019): 11. http://dx.doi.org/10.1051/mbcb/2018027.

Full text

Abstract:

Introduction: Mucositis is a well-known side effect of classic anticancer treatments (chemotherapy and radiotherapy). Thanks to the major developments in personalizing treatments through the development of targeted treatment, various specific intraoral lesions have been described. Purpose: mTOR inhibitors are targeted anticancer treatments that are used to treat various cancer types. They can cause intraoral ulcerations that can be serious, and that can lead to a dose reduction or the anticancer treatment being stopped altogether. The management of these disabling and painful lesions is a majo

APA, Harvard, Vancouver, ISO, and other styles

9

Robert, Caroline, Vincent Sibaud, Christina Mateus, et al. "Nail toxicities induced by systemic anticancer treatments." Lancet Oncology 16, no. 4 (2015): e181-e189. http://dx.doi.org/10.1016/s1470-2045(14)71133-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Carlson, Robert H. "Common Bacteria Integral to New Anticancer Treatments." Oncology Times 23, no. 6 (2001): 67–68. http://dx.doi.org/10.1097/01.cot.0000315765.11795.e5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Ricard, Damien, Hervé Taillia, and Jean-Luc Renard. "Brain damage from anticancer treatments in adults." Current Opinion in Oncology 21, no. 6 (2009): 559–65. http://dx.doi.org/10.1097/cco.0b013e328330c669.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Tang, Daolin, Oliver Kepp, and Guido Kroemer. "Ferroptosis becomes immunogenic: implications for anticancer treatments." OncoImmunology 10, no. 1 (2020): 1862949. http://dx.doi.org/10.1080/2162402x.2020.1862949.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ben-Aharon, Irit, and Ruth Shalgi. "What lies behind chemotherapy-induced ovarian toxicity?" REPRODUCTION 144, no. 2 (2012): 153–63. http://dx.doi.org/10.1530/rep-12-0121.

Full text

Abstract:

Seminal advances in anticancer therapy as well as supportive care strategies have led to improved survival rates, posing an emphasis on preserving an optimum quality of life after cancer treatment. This recognition has paved the way to an increasing research of long-term side effects, both clinical and preclinical and to an ongoing design of a supportive care system to evaluate and treat long-term adverse effects of anticancer treatments, including the impact on fertility. As with many adverse effects induced by anticancer treatments, the literature comprised mostly clinical data with regard t

APA, Harvard, Vancouver, ISO, and other styles

14

Tripathi, Nishita, Daniya Sheikh, and Demetra Antimisiaris. "Anticancer Therapy in COVID-19 Patients: A Descriptive Literature Review." Senior Care Pharmacist 36, no. 8 (2021): 365–74. http://dx.doi.org/10.4140/tcp.n.2021.365.

Full text

Abstract:

Objective: To provide a descriptive literature review about the effects of anticancer treatment on clinical outcomes because of active COVID-19 infection in older people. Data Sources: A literature search was conducted in Google Scholar, PubMed, American Society of Clinical Oncology, European Society for Medical Oncology, and the Center for Disease Control and Prevention. Articles published in English between December 1, 2019, to September 1, 2020, were included. Study Selection: Nine studies assessing the effectiveness of various modalities for cancer treatments in patients infected with COVI

APA, Harvard, Vancouver, ISO, and other styles

15

Villéger, Romain, Amélie Lopès, Guillaume Carrier, et al. "Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?" International Journal of Molecular Sciences 20, no. 18 (2019): 4584. http://dx.doi.org/10.3390/ijms20184584.

Full text

Abstract:

Recently, preclinical and clinical studies targeting several types of cancer strongly supported the key role of the gut microbiota in the modulation of host response to anti-tumoral therapies such as chemotherapy, immunotherapy, radiotherapy and even surgery. Intestinal microbiome has been shown to participate in the resistance to a wide range of anticancer treatments by direct interaction with the treatment or by indirectly stimulating host response through immunomodulation. Interestingly, these effects were described on colorectal cancer but also in other types of malignancies. In addition t

APA, Harvard, Vancouver, ISO, and other styles

16

Omori, Shota, Hirotsugu Kenmotsu, Koji Muramatsu, et al. "Changes in TROP2 expression in lung cancer patients receiving anticancer treatments." Journal of Clinical Oncology 37, no. 15_suppl (2019): e14732-e14732. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14732.

Full text

Abstract:

e14732 Background: Human trophoblast cell surface glycoprotein (TROP2) is expressed on the cell surface of trophoblasts and various solid cancer cells. Recently, an antibody-drug conjugate (ADC) targeting TROP2 has been developed. The objective of this retrospective study is to evaluate the prevalence of TROP2 expression in the specimen of lung cancer and its changes during anticancer treatments. Methods: TROP2 expression was evaluated prior to and following anticancer treatment by immunohistochemical (IHC) analysis using an anti-TROP2 antibody (SP295). IHC scores were graded from 0 to 3 and g

APA, Harvard, Vancouver, ISO, and other styles

17

Curigliano, Giuseppe, Daniela Cardinale, Susan Dent, et al. "Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management." CA: A Cancer Journal for Clinicians 66, no. 4 (2016): 309–25. http://dx.doi.org/10.3322/caac.21341.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Geoffrion, Luke D., Tina Hesabizadeh, David Medina-Cruz, et al. "Naked Selenium Nanoparticles for Antibacterial and Anticancer Treatments." ACS Omega 5, no. 6 (2020): 2660–69. http://dx.doi.org/10.1021/acsomega.9b03172.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Elsayed, Yusri A., and Edward A. Sausville. "Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins." Oncologist 6, no. 6 (2001): 517–37. http://dx.doi.org/10.1634/theoncologist.6-6-517.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Vallet, Nicolas, Nicolas Boissel, Elisabeth Elefant, et al. "Can Some Anticancer Treatments Preserve the Ovarian Reserve?" Oncologist 26, no. 6 (2021): 492–503. http://dx.doi.org/10.1002/onco.13675.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wishart, Gabrielle, Priyanka Gupta, Andrew Nisbet, Eirini Velliou, and Giuseppe Schettino. "Novel Anticancer and Treatment Sensitizing Compounds against Pancreatic Cancer." Cancers 13, no. 12 (2021): 2940. http://dx.doi.org/10.3390/cancers13122940.

Full text

Abstract:

The isolation of chemical compounds from natural origins for medical application has played an important role in modern medicine with a range of novel treatments having emerged from various natural forms over the past decades. Natural compounds have been exploited for their antioxidant, antimicrobial and antitumor capabilities. Specifically, 60% of today’s anticancer drugs originate from natural sources. Moreover, the combination of synthetic and natural treatments has shown applications for (i) reduced side effects, (ii) treatment sensitization and (iii) reduction in treatment resistance. Thi

APA, Harvard, Vancouver, ISO, and other styles

22

Delou, Souza, Souza, and Borges. "Highlights in Resistance Mechanism Pathways for Combination Therapy." Cells 8, no. 9 (2019): 1013. http://dx.doi.org/10.3390/cells8091013.

Full text

Abstract:

Combination chemotherapy has been a mainstay in cancer treatment for the last 60 years. Although the mechanisms of action and signaling pathways affected by most treatments with single antineoplastic agents might be relatively well understood, most combinations remain poorly understood. This review presents the most common alterations of signaling pathways in response to cytotoxic and targeted anticancer drug treatments, with a discussion of how the knowledge of signaling pathways might support and orient the development of innovative strategies for anticancer combination therapy. The ultimate

APA, Harvard, Vancouver, ISO, and other styles

23

Howard, David H. "Realigning Incentives for Developing and Pricing New Anticancer Treatments." JAMA 305, no. 22 (2011): 2347. http://dx.doi.org/10.1001/jama.2011.793.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Biroccio, Annamaria, Carlo Leonetti, and Gabriella Zupi. "The future of antisense therapy: combination with anticancer treatments." Oncogene 22, no. 42 (2003): 6579–88. http://dx.doi.org/10.1038/sj.onc.1206812.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Geisberg, Carrie, Laura Pentassuglia, and Douglas B. Sawyer. "Cardiac Side Effects of Anticancer Treatments: New Mechanistic Insights." Current Heart Failure Reports 9, no. 3 (2012): 211–18. http://dx.doi.org/10.1007/s11897-012-0098-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Abdelgawad, Ibrahim, Marianne Grant, and Beshay Zordoky. "Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology." Nutrients 11, no. 3 (2019): 627. http://dx.doi.org/10.3390/nu11030627.

Full text

Abstract:

Cardio-oncology is a clinical/scientific discipline which aims to prevent and/or treat cardiovascular diseases in cancer patients. Although a large number of cancer treatments are known to cause cardiovascular toxicity, they are still widely used because they are highly effective. Unfortunately, therapeutic interventions to prevent and/or treat cancer treatment-induced cardiovascular toxicity have not been established yet. A major challenge for such interventions is to protect the cardiovascular system without compromising the therapeutic benefit of anticancer medications. Intriguingly, the po

APA, Harvard, Vancouver, ISO, and other styles

27

Lee, Jun H., and Anjan Nan. "Combination Drug Delivery Approaches in Metastatic Breast Cancer." Journal of Drug Delivery 2012 (April 26, 2012): 1–17. http://dx.doi.org/10.1155/2012/915375.

Full text

Abstract:

Disseminated metastatic breast cancer needs aggressive treatment due to its reduced response to anticancer treatment and hence low survival and quality of life. Although in theory a combination drug therapy has advantages over single-agent therapy, no appreciable survival enhancement is generally reported whereas increased toxicity is frequently seen in combination treatment especially in chemotherapy. Currently used combination treatments in metastatic breast cancer will be discussed with their challenges leading to the introduction of novel combination anticancer drug delivery systems that a

APA, Harvard, Vancouver, ISO, and other styles

28

Miner, Michał, Michał Elbaum, Aleksandra Jawiarczyk-Przybyłowska, and Eliza Kubicka. "Endocrine complications of new anticancer therapies." Postępy Higieny i Medycyny Doświadczalnej 75 (March 18, 2021): 191–98. http://dx.doi.org/10.5604/01.3001.0014.8121.

Full text

Abstract:

Studying and analyzing of complex molecular mechanisms and immunological processes of cancer enables oncology to introduce new cancer therapies. In the treatment of cancer, we successively increase the use of targeted therapies with tyrosine kinase inhibitors and mTOR inhibitors and immunotherapy using checkpoint inhibitors CTLA-4 (cytotoxic T-cell antigen-4) and PD-1/PD-L1 (programmed death receptor 1/programmed death ligand 1). New anticancer drugs gradually replace conventional chemotherapy and have already found application in the treatment of many cancers, including thyroid cancer, hepato

APA, Harvard, Vancouver, ISO, and other styles

29

Gandhi, M., C. Calahan, K. Oishi, and M. Lacouture. "Unexpected dermatologic toxicities from anticancer therapies: Survivors’ perspectives." Journal of Clinical Oncology 27, no. 15_suppl (2009): e20673-e20673. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e20673.

Full text

Abstract:

e20673 Background: As oncologic therapies have shown improved survival, there is a growing attention to other aspects of the cancer experience from the survivors’ perspectives. Gastrointestinal, constitutional, and dermatologic toxicities are frequently experienced and further study of their impact is important to prevent inconsistent antineoplastic drug administration. This study is aimed to evaluate survivors’ perceptions of unexpected toxicities. Methods: CancerCare, a national nonprofit organization, mailed 1,369 surveys to cancer survivors completing their treatment. The survey divided in

APA, Harvard, Vancouver, ISO, and other styles

30

Méresse, Sarah, Mostefa Fodil, Fabrice Fleury, and Benoît Chénais. "Fucoxanthin, a Marine-Derived Carotenoid from Brown Seaweeds and Microalgae: A Promising Bioactive Compound for Cancer Therapy." International Journal of Molecular Sciences 21, no. 23 (2020): 9273. http://dx.doi.org/10.3390/ijms21239273.

Full text

Abstract:

Fucoxanthin is a well-known carotenoid of the xanthophyll family, mainly produced by marine organisms such as the macroalgae of the fucus genus or microalgae such as Phaeodactylum tricornutum. Fucoxanthin has antioxidant and anti-inflammatory properties but also several anticancer effects. Fucoxanthin induces cell growth arrest, apoptosis, and/or autophagy in several cancer cell lines as well as in animal models of cancer. Fucoxanthin treatment leads to the inhibition of metastasis-related migration, invasion, epithelial–mesenchymal transition, and angiogenesis. Fucoxanthin also affects the DN

APA, Harvard, Vancouver, ISO, and other styles

31

Yan, Xinjia, Jing Wen, Lin Zhou, Lei Fan, Xiaobo Wang, and Zhi Xu. "Current Scenario of 1,3-oxazole Derivatives for Anticancer Activity." Current Topics in Medicinal Chemistry 20, no. 21 (2020): 1916–37. http://dx.doi.org/10.2174/1568026620666200624161151.

Full text

Abstract:

Cancer, which has been cursed for human beings for long time is considered as one of the leading causes of morbidity and mortality across the world. In spite of different types of treatments available, chemotherapy is still deemed as a favored treatment for the cancer. Unfortunately, many currently accessible anticancer agents have developed multidrug resistance along with fatal adverse effects. Therefore, intensive efforts have been made to seek for new active drugs with improved anticancer efficacy and reduced adverse effects. In recent years, the emergence of heterocyclic ring-containing an

APA, Harvard, Vancouver, ISO, and other styles

32

Gori, Stefania, Massimo Di Maio, Carmine Pinto, et al. "Impact of use of Oral Anticancer Drugs on Activity of Italian Oncology Practices: Results of a Survey Conducted by the Italian Society of Medical Oncology (AIOM)." Tumori Journal 99, no. 1 (2013): 35–38. http://dx.doi.org/10.1177/030089161309900106.

Full text

Abstract:

Aims and background In recent years, the number of oral anticancer drugs used in clinical practice has rapidly increased. The Italian Society of Medical Oncology (AIOM) conducted a survey to describe the impact of the use of oral anticancer drugs on the daily activity of Italian oncology practices. Methods and study design A survey questionnaire was distributed to the coordinators of the regional sections of AIOM. A 6-month period was considered, from January 1, 2010 to June 30, 2010. The survey addressed (1) quantitative aspects of the use of oral anticancer drugs; (2) practical aspects in th

APA, Harvard, Vancouver, ISO, and other styles

33

Lee, Gap Ryol. "Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells." Mediators of Inflammation 2017 (2017): 1–9. http://dx.doi.org/10.1155/2017/5458178.

Full text

Abstract:

Regulatory T (Treg) cells maintain immune homeostasis by suppressing excessive immune responses. Treg cells induce tolerance against self- and foreign antigens, thus preventing autoimmunity, allergy, graft rejection, and fetus rejection during pregnancy. However, Treg cells also infiltrate into tumors and inhibit antitumor immune responses, thus inhibiting anticancer therapy. Depleting whole Treg cell populations in the body to enhance anticancer treatments will produce deleterious autoimmune diseases. Therefore, understanding the precise nature of tumor-infiltrating Treg cells is essential fo

APA, Harvard, Vancouver, ISO, and other styles

34

Ewer, Michael S., and Steven M. Ewer. "Cardiotoxicity of anticancer treatments: what the cardiologist needs to know." Nature Reviews Cardiology 7, no. 10 (2010): 564–75. http://dx.doi.org/10.1038/nrcardio.2010.121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Falcetta, Francesca, Monica Lupi, Valentina Colombo, and Paolo Ubezio. "Dynamic Rendering of the Heterogeneous Cell Response to Anticancer Treatments." PLoS Computational Biology 9, no. 10 (2013): e1003293. http://dx.doi.org/10.1371/journal.pcbi.1003293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Jouinot, Anne, Clara Vazeille, Jean Philippe Durand, et al. "Resting energy expenditure in the risk assessment of anticancer treatments." Clinical Nutrition 37, no. 2 (2018): 558–65. http://dx.doi.org/10.1016/j.clnu.2017.01.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Weckbecker, G., M. Pollak, L. Tolcsval, B. Stolz, C. Bruns, and Sandoz Pharma. "Somatostatin analog octreotide (SMS 201–995) enhances endocrine anticancer treatments." Pharmacological Research 31 (January 1995): 31. http://dx.doi.org/10.1016/1043-6618(95)86384-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

He, Chuanchuan, Xiaojuan Zhang, and Guangya Xiang. "Nanoparticle facilitated delivery of peroxides for effective cancer treatments." Biomaterials Science 8, no. 20 (2020): 5574–82. http://dx.doi.org/10.1039/d0bm01265c.

Full text

Abstract:

Peroxide nanoparticles increase the intratumoral H<sub>2</sub>O<sub>2</sub> concentration for the catalytic production of ˙OH and O<sub>2</sub>, which further enhance O<sub>2</sub>/ROS-dependent anticancer therapies.

APA, Harvard, Vancouver, ISO, and other styles

39

Milczarek, Małgorzata, Anna Pogorzelska, and Katarzyna Wiktorska. "Synergistic Interaction between 5-FU and an Analog of Sulforaphane—2-Oxohexyl Isothiocyanate—In an In Vitro Colon Cancer Model." Molecules 26, no. 10 (2021): 3019. http://dx.doi.org/10.3390/molecules26103019.

Full text

Abstract:

Combination therapy is based on the beneficial effects of pharmacodynamic interaction (synergistic or additive) between combined drugs or substances. A considerable group of candidates for combined treatments are natural compounds (e.g., isothiocyanates) and their analogs, which are tested in combination with anticancer drugs. We tested the anticancer effect of the combined treatment of isothiocyanate 2-oxohexyl isothiocyanate and 5-fluorouracil in colon and prostate cancer cell lines. The type of interaction was described using the Chou-Talalay method. The cytostatic and cytotoxic activities

APA, Harvard, Vancouver, ISO, and other styles

40

Akhtari, Farida S., Adrian J. Green, George W. Small, et al. "High-throughput screening and genome-wide analyses of 44 anticancer drugs in the 1000 Genomes cell lines reveals an association of the NQO1 gene with the response of multiple anticancer drugs." PLOS Genetics 17, no. 8 (2021): e1009732. http://dx.doi.org/10.1371/journal.pgen.1009732.

Full text

Abstract:

Cancer patients exhibit a broad range of inter-individual variability in response and toxicity to widely used anticancer drugs, and genetic variation is a major contributor to this variability. To identify new genes that influence the response of 44 FDA-approved anticancer drug treatments widely used to treat various types of cancer, we conducted high-throughput screening and genome-wide association mapping using 680 lymphoblastoid cell lines from the 1000 Genomes Project. The drug treatments considered in this study represent nine drug classes widely used in the treatment of cancer in additio

APA, Harvard, Vancouver, ISO, and other styles

41

Prentice, Mark, Kenneth Man, Yogini Jani, Heather Ann Payne, and Ian Wong. "Computer modelling in prostate anticancer therapy (COMPACT)." Journal of Clinical Oncology 37, no. 15_suppl (2019): e16528-e16528. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e16528.

Full text

Abstract:

e16528 Background: Prostate cancer is the most common solid malignancy in men and despite improving radical therapies a proportion of patients will develop castrate resistant metastatic disease (mCRPC). Therapeutic options in mCRPC include abiraterone acetate and prednisolone (AA+P), enzalutamide (E) and docetaxel (D) with limited evidence to guide clinical choice between agents. COMPACT aims to collate data from multiple data sets within one hospital to assess clinical or biochemical factors that may guide therapeutic strategy. Methods: Data was collated on all patients recorded as receiving

APA, Harvard, Vancouver, ISO, and other styles

42

Ng, Chau Yee, Chun-Bing Chen, Ming-Ying Wu, et al. "Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies." Journal of Immunology Research 2018 (2018): 1–9. http://dx.doi.org/10.1155/2018/5376476.

Full text

Abstract:

Cutaneous adverse drug reactions are commonly seen in patients with anticancer drug treatment. Anticancer drugs, including chemotherapy, target therapy, and recent immunotherapy causing skin reactions ranging from mild skin rash to life-threatening severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) with increase morbidity and mortality while they are receiving cancer treatments, have been proposed to be a result of direct skin toxicity or drug hypersensitivity reactions (these are proposed mechanism, not definite). Differentiat

APA, Harvard, Vancouver, ISO, and other styles

43

Talib, Wamidh H., Izzeddin Alsalahat, Safa Daoud, Reem Fawaz Abutayeh, and Asma Ismail Mahmod. "Plant-Derived Natural Products in Cancer Research: Extraction, Mechanism of Action, and Drug Formulation." Molecules 25, no. 22 (2020): 5319. http://dx.doi.org/10.3390/molecules25225319.

Full text

Abstract:

Cancer is one of the main causes of death globally and considered as a major challenge for the public health system. The high toxicity and the lack of selectivity of conventional anticancer therapies make the search for alternative treatments a priority. In this review, we describe the main plant-derived natural products used as anticancer agents. Natural sources, extraction methods, anticancer mechanisms, clinical studies, and pharmaceutical formulation are discussed in this review. Studies covered by this review should provide a solid foundation for researchers and physicians to enhance basi

APA, Harvard, Vancouver, ISO, and other styles

44

Chou, Yi-Ting, Joel F. Farley, Thomas E. Stinchcombe, Amber E. Proctor, Jennifer Elston Lafata, and Stacie B. Dusetzina. "The Association Between Medicare Low-Income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer." JNCI: Journal of the National Cancer Institute 112, no. 6 (2019): 637–46. http://dx.doi.org/10.1093/jnci/djz183.

Full text

Abstract:

Abstract Background High out-of-pocket costs may impact anticancer treatment uptake. The Low-Income Subsidy (LIS) program can reduce patient out-of-pocket cost for Medicare Part D–covered treatments. We examined whether the LIS increased uptake and reduced time to initiate orally administered anticancer drugs in patients with advanced non–small cell lung cancer (NSCLC). Methods Using Surveillance, Epidemiology and End Results (SEER)-Medicare data, we identified older adults (aged 65 years and older) diagnosed with advanced NSCLC from 2007 through 2013 and categorized them as full LIS, partial

APA, Harvard, Vancouver, ISO, and other styles

45

Nguyen, Oanh Thi-Kieu. "Evaluation the effect of several anticancer drugs on Vietnamese breast cancer cells." Science and Technology Development Journal 21, no. 2 (2018): 44–51. http://dx.doi.org/10.32508/stdj.v21i2.488.

Full text

Abstract:

In Viet Nam, data from Conference of Cancer organized by the Ministry of Health has shown that breast cancer is the most popular cancer in women. Current mainly treatments are surgery, chemotherapy, and radiotherapy. However, the rate of recurrence after five years was very high. One of the causes of high relapse is cancer cells develop multidrug-resistant (MDR) thus reduced the efficiency of treatments. In this research, MTT assay was used for measured cell viability of Vietnamese breast cancer cells (VNBRCA cells) and positive control MCF-7 cell lines after treatment with several anticancer

APA, Harvard, Vancouver, ISO, and other styles

46

Gyanani, Vijay, Jeffrey C. Haley, and Roshan Goswami. "Challenges of Current Anticancer Treatment Approaches with Focus on Liposomal Drug Delivery Systems." Pharmaceuticals 14, no. 9 (2021): 835. http://dx.doi.org/10.3390/ph14090835.

Full text

Abstract:

According to a 2020 World Health Organization report (Globocan 2020), cancer was a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. The aim of anticancer therapy is to specifically inhibit the growth of cancer cells while sparing normal dividing cells. Conventional chemotherapy, radiotherapy and surgical treatments have often been plagued by the frequency and severity of side effects as well as severe patient discomfort. Cancer targeting by drug delivery systems, owing to their selective targeting, efficacy, biocompatibility and high drug payload, provides an

APA, Harvard, Vancouver, ISO, and other styles

47

Gurunathan, Sangiliyandi, Min-Hee Kang, Muhammad Qasim, and Jin-Hoi Kim. "Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer." International Journal of Molecular Sciences 19, no. 10 (2018): 3264. http://dx.doi.org/10.3390/ijms19103264.

Full text

Abstract:

Cancer represents a group of heterogeneous diseases characterized by uncontrolled growth and spread of abnormal cells, ultimately leading to death. Nanomedicine plays a significant role in the development of nanodrugs, nanodevices, drug delivery systems and nanocarriers. Some of the major issues in the treatment of cancer are multidrug resistance (MDR), narrow therapeutic window and undesired side effects of available anticancer drugs and the limitations of anticancer drugs. Several nanosystems being utilized for detection, diagnosis and treatment such as theranostic carriers, liposomes, carbo

APA, Harvard, Vancouver, ISO, and other styles

48

Gattellari, Melina, Katie J. Voigt, Phyllis N. Butow, and Martin H. N. Tattersall. "When the Treatment Goal Is Not Cure: Are Cancer Patients Equipped to Make Informed Decisions?" Journal of Clinical Oncology 20, no. 2 (2002): 503–13. http://dx.doi.org/10.1200/jco.2002.20.2.503.

Full text

Abstract:

PURPOSE: Informed decision making now is considered the underpinning of ethical medical practice. We aimed to determine the extent to which patients with incurable cancer are adequately informed of their prognosis and treatment options and encouraged to participate in treatment decisions. PATIENTS AND METHODS: One hundred eighteen cancer patients with incurable disease presenting for an initial consultation with one of nine oncologists at two Sydney tertiary referral hospitals participated in the study. Consultations were recorded on audiotape to permit a content analysis of doctor-patient int

APA, Harvard, Vancouver, ISO, and other styles

49

Van Loenhout, Jinthe, Marc Peeters, Annemie Bogaerts, Evelien Smits, and Christophe Deben. "Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects." Antioxidants 9, no. 12 (2020): 1188. http://dx.doi.org/10.3390/antiox9121188.

Full text

Abstract:

Cancer cells are characterized by higher levels of reactive oxygen species (ROS) compared to normal cells as a result of an imbalance between oxidants and antioxidants. However, cancer cells maintain their redox balance due to their high antioxidant capacity. Recently, a high level of oxidative stress is considered a novel target for anticancer therapy. This can be induced by increasing exogenous ROS and/or inhibiting the endogenous protective antioxidant system. Additionally, the immune system has been shown to be a significant ally in the fight against cancer. Since ROS levels are important

APA, Harvard, Vancouver, ISO, and other styles

50

Ma, Meng, Kyeryoung Lee, Yun Mai, et al. "Extracting longitudinal anticancer treatments at scale using deep natural language processing and temporal reasoning." Journal of Clinical Oncology 39, no. 15_suppl (2021): e18747-e18747. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e18747.

Full text

Abstract:

e18747 Background: Accurate longitudinal cancer treatments are vital for establishing primary endpoints such as outcome as well as for the investigation of adverse events. However, many longitudinal therapeutic regimens are not well captured in structured electronic health records (EHRs). Thus, their recognition in unstructured data such as clinical notes is critical to gain an accurate description of the real-world patient treatment journey. Here, we demonstrate a scalable approach to extract high-quality longitudinal cancer treatments from lung cancer patients' clinical notes using a Bidirec

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!